Meiling Zhang

Meiling Zhang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
BZBei Zheng
Bei Zheng
QZQinqin Zhao
Qinqin Zhao
WYWenjuan Yang
Wenjuan Yang
PFPinpin Feng
Pinpin Feng
CXChuanwei Xin
Chuanwei Xin
GLGong-hua Li
Gong-hua Li
This study aimed to explore the efficacy and safety of small-molecule antivirals for treating coronavirus disease 2019 (COVID-19). Seven databases were searched from their inception to 01 June 2023. The risk of bias in randomised controlled trials and retrospective studies was evaluated individually using the Cochrane risk-of-bias tool and Newcastle Ottawa Scale. In total, 160 studies involving 933 409 COVID-19 patients were evaluated. Compared with placebo or standard of care, proxalutamide demonstrated remarkable efficacy in reducing mortality rates, hospitalisation rates, serious adverse events, and the need for mechanical ventilation. Furthermore, it significantly enhanced both the rate of clinical improvement and expedited the duration of clinical recovery when compared with control groups. In patients with mild-to-moderate COVID-19, proxalutamide exhibited the above advantages, except for mortality reduction. Triazavirin was the most effective treatment for reducing the time required for viral clearance and improving the discharge rate. Leritrelvir and VV116 were ranked first in terms of enhancing the viral clearance rate on days 7 and 14, respectively. Molnupiravir was the most effective treatment for reducing the need for oxygen support. Overall, these findings remained consistent across the various subgroups. A thorough evaluation of effectiveness, applicable to both mild-to-moderate and unstratified populations, highlights the specific advantages of proxalutamide, nirmatrelvir/ritonavir, triazavirin, azvudine, molnupiravir, and VV116 in combating COVID-19. Additional clinical data are required to confirm the efficacy and safety of simnotrelvir/ritonavir and leritrelvir. The safety profiles of these antivirals were deemed acceptable.

2 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CXChuanwei Xin
Chuanwei Xin
BYBo Yang
Bo Yang
LPLisha Pang
Lisha Pang
BZBei Zheng
Bei Zheng
BHBing Han
Bing Han
YTYue-Xing Tu
Yue-Xing Tu
Antimicrobial Stewardship Programs (ASP) have demonstrated efficacy in lowering hospital expenditures and enhancing the judicious use of antibiotics. However, many hospitals in China have not yet established an ASP management model, and there is limited literature reporting successful ASP experiences. This study aimed to investigate the impact of ASP on Antibiotics Use Density (AUD). We conducted a retrospective study from October 2023 to September 2024 in a tertiary general hospital in Hangzhou, China. Based on audits of antibiotic orders conducted from October 1, 2023, to March 31, 2024, we identified potential factors contributing to high AUD. In line with the guidelines for implementing ASP, we established an ASP team and implemented comprehensive improvement strategies from April 1, 2024, to September 30, 2024. Following the implementation of ASP, the AUD decreased significantly by 31.01% from 54.20 prior to intervention to 37.39 post-intervention. The total Defined Daily Doses (DDDS) declined by 30.06% from 98,311.52 to 68,751.82, while the total cost of antibiotics fell by 5.81% from $1,798,309.53 to $1,693,918.44. Among 33 clinical departments within the hospital, 31 demonstrated a reduction in AUD. Furthermore, the AUD proportion of tetracyclines and quinolone antibacterials decreased from 6.68 to 2.54% and from 25.63 to 21.10%, respectively. This study demonstrates that ASP is a viable and effective approach for reducing AUD and DDDS of antibiotics, as well as lowering the overall cost of antibiotics, and has the potential to enhance the quality of antimicrobial prescribing.

19 June 2023 in Cancer Medicine
Verified
Journal Article
Open access
BZBei Zheng
Bei Zheng
HJHong Jiang
Hong Jiang
WYWenjuan Yang
Wenjuan Yang
YLYing Li
Ying Li
BLBingqing Liang
Bingqing Liang
MZMeiling Zhang
Meiling Zhang
Objective: To date, no direct comparisons have compared the effectiveness of all ALK inhibitors (ALKis) against ALK‐positive non‐small cell lung cancer (NSCLC). The aim of the present study was to investigate the efficacy and safety of ALKis in ALK‐positive NSCLC.Methods: The effectiveness of ALKis was evaluated by assessing progression‐free survival (PFS), overall survival (OS), overall response rate (ORR), and PFS with baseline brain metastasis (BM). The serious adverse events (SAEs: Grade ≥ 3) and adverse events (AEs) leading to discontinuation were pooled to evaluate safety. We conducted an indirect treatment comparison between all ALKis by using a Bayesian model.Results: Twelve eligible trials including seven treatments were identified. All of the ALKis improved PFS and ORR relative to chemotherapy. Consistent with alectinib, brigatinib, lorlatinib, and ensartinib showed significant differences versus crizotinib and ceritinib. Lorlatinib seemed to prolong PFS compared with alectinib (0.64, 0.37 to 1.07), brigatinib (0.56, 0.3 to 1.05), and ensartinib (0.53, 0.28 to 1.02). No significant difference was found among them in OS except for alectinib versus crizotinib. Moreover, alectinib was significantly more effective than crizotinib (1.54, 1.02 to 2.5) in achieving the best ORR. Subgroup analyses based on BM indicated that PFS was dramatically lengthened by lorlatinib. Compared with other ALKis, alectinib notably reduced the rate of SAEs. There was no striking difference between discontinuation for AEs, except for ceritinib versus crizotinib. The ranking of validity showed that lorlatinib had the longest PFS (98.32%) and PFS with BM (85.84%) and the highest ORR (77.01%). The rank of probabilities showed that alectinib had the potentially best safety in terms of SAEs (97.85%), and ceritinib had less discontinuation (95.45%).Conclusion: Alectinib was the first choice for patients with ALK‐positive NSCLC and even for those with BM, whereas lorlatinib was the second choice. Long‐term follow‐up and prospective studies are warranted to compare ALKis and to verify our conclusions directly.

20 September 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YSYunfeng Sun
Yunfeng Sun
ZXZhongni Xia
Zhongni Xia
QZQinqin Zhao
Qinqin Zhao
BZBei Zheng
Bei Zheng
MZMeiling Zhang
Meiling Zhang
YYYin Ying
Yin Ying
Research has shown that FMS-like tyrosine kinase 3 (FLT3) may be a vital drug target for acute myeloid leukemia (AML). However, even though the clinically relevant F691L gatekeeper mutation conferred resistance to current FLT3 drug quizartinib, PLX3397 remained unaffected. In this study, the protein–ligand interactions between FLT3 kinase domain (wild-type or F691L) and quizartinib or PLX3397 were compared via an integrated computational approach. The classical molecular dynamics (MD) simulations in conjunction with dynamic cross-correlation (DCC) analysis, solvent-accessible surface area (SASA), and free energy calculations indicated that the resistant mutation may induce the conformational change of αC-helix and A-loop of the FLT3 protein. The major variations were controlled by the electrostatic interaction and SASA, which were allosterically regulated by residues Glu-661 and Asp-829. When FLT3-F691L was bound to quizartinib, a large conformational change was observed via combination of accelerated MD simulations (aMDs), principal component analysis (PCA), and free energy landscape (FEL) calculations. The umbrella sampling (US) simulations were applied to investigate the dissociation processes of the quizartinib or PLX3397 from FLT3-WT and FLT3-F691L. The calculated results suggested that PLX3397 had similar dissociation processes from both FLT3-WT and FLT3-F691L, but quizartinib dissociated more easily from FLT3-F691L than from FLT3-WT. Thus, reduced residence time was responsible for the FLT3-F691L resistance to inhibitors. These findings indicated that both the conformational changes of αC-helix and A-loop and the drug residence time should be considered in the design of drugs so that rational decisions can be made to overcome resistance to FLT3-F691L.

29 August 2025 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
BZBei Zheng
Bei Zheng
CXChuanwei Xin
Chuanwei Xin
YLYizhuo Liu
Yizhuo Liu
ELEnhui Lv
Enhui Lv
HJHuifang Jiang
Huifang Jiang
YTYue-Xing Tu
Yue-Xing Tu
Introduction Early antibacterial treatment is critical for patients with hematologic malignancies (HMs) and sepsis. Droplet digital polymerase chain reaction (ddPCR) can rapidly detect pathogens and antimicrobial resistance (AMR) genes, but its clinical value in HMs is unknown. This study aimed to systematically evaluate the role of ddPCR in diagnosis, clinical outcomes, and antimicrobial stewardship. Methods From January 2023 to March 2025, 400 patients with hematologic malignancies (HMs) and sepsis were enrolled in the study. Of these, 150 received both ddPCR and blood culture (BC), while 250 underwent BC alone. Using propensity score matching (PSM), as well as subgroup and sensitivity analyses, we evaluated ten indicators, including 28-day mortality, treatment efficacy, and antibiotic use density (AUD). Results ddPCR showed a 49.33% positive rate (vs. BC’s 17.50%, P < 0.01) with a 4.06-h diagnostic turnaround (vs. 72.47 h for BC, P < 0.01), achieving 70.37% sensitivity and 55.28% specificity. The ddPCR group had lower 28-day mortality (HR = 0.55, P = 0.01), higher clinical response rates, and greater inflammatory marker decline. Antimicrobial optimization via ddPCR improved efficacy to 85.11%, with reduced AUD (OR = − 28.93, P < 0.01), the quantity and proportion of combined antimicrobial usage. However, a non-significant difference was observed in the proportion of antibacterial treatment costs (P = 0.14). PSM and sensitivity analysis results were consistent, indicating data robustness. Conclusions ddPCR outperforms BC in diagnostic efficiency for patients with HMs and sepsis, accelerating pathogen and AMR genes identification, optimizing antibacterial therapy and management, improving clinical effectiveness, and reducing 28-day all-cause mortality. The findings support the application of ddPCR in immunosuppressed populations. Graphical Abstract

8 July 2024 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
WYWenjuan Yang
Wenjuan Yang
DHDanhong Hu
Danhong Hu
BZBei Zheng
Bei Zheng
BHBing Han
Bing Han
PFPingping Feng
Pingping Feng
MZMeiling Zhang
Meiling Zhang
Background: Rash is one of common adverse drug reaction and which have been reported in typical and atypical antipsychotics. Reports of lurasidone induced skin reactions are sparse. In this study, we report a case of rash caused by lurasidone. Case presentation: A 63-year-old man with bipolar disorder (BD) who is treated by lurasidone. However, the patient presents a rash all over after lurasidone dose increasing from 40 mg/day to 60 mg/day. With the diagnosis of drug induced rash, lurasidone was discontinued, and the rash complete disappears within 2 weeks. In addition, all case reports about antipsychotics associated rash were reviewed by searching English and Chinese database including Pubmed, Embase, Cochrane Library, CNKI and Wanfang database. A total of 139 articles contained 172 patients were included in our study. The literature review and our case suggest that the cutaneous adverse events caused by antipsychotic drugs should not be ignored, particularly for the patient who was first use or at dose increasing of antipsychotic. Conclusions: In conclusion, we report a case of lurasidone related rash and review rash caused by antipsychotics. Psychiatrists should be alert to the possibility of the rash caused by antipsychotics, especially the patient was first use of antipsychotics or the antipsychotic dose was increasing.